Cannabis Market Performance: Cannabis companies experienced significant declines on Wall Street, with major U.S. multi-state operators like Curaleaf and Trulieve seeing double-digit percentage drops, while Canadian producers outperformed.
Trump's Executive Order: President Trump's anticipated executive order aims to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act, recognizing its medical value and lower abuse potential.
Impact on ETFs: Cannabis-focused ETFs, including AdvisorShares Pure US Cannabis ETF and Amplify Seymour Cannabis ETF, fell approximately 12%, reflecting the overall market downturn amid the news of the executive order.
Political Opposition: Some political figures, such as GOP Rep. Lawler, have expressed opposition to the rescheduling plan, labeling marijuana as a "gateway drug."
Wall Street analysts forecast MSOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MSOS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast MSOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MSOS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 4.620
Low
Averages
High
Current: 4.620
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
